XML 18 R7.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Cash flows from operating activities:              
Net loss $ (108,497,311) $ (79,073,719) $ (82,139,958) $ (54,402,131) $ (187,571,030) $ (136,542,089)  
Adjustments to reconcile net loss to net cash used in operating activities:              
Depreciation         1,869,961 1,361,595  
Amortization of intangible assets 131,000   130,000   257,327 266,874  
Amortization of operating lease right-of-use assets         658,501 567,882  
Non-cash stock-based compensation         16,047,204 15,242,305  
Non-cash interest expense         93,489 435,445  
Amortization of premiums on investments         (72,833) 0  
(Gain) loss on short-term investments         320,942 (153,252)  
Loss on disposal of fixed assets         157,666 0  
Gain on remeasurement of investment in Geneos         (165,215) 0  
Loss on equity investment in affiliated entities 934,015   (278,818)   1,471,743 551,657  
Share of net loss in Geneos 0   0   2,165,213 434,387  
Net unrealized loss on available-for-sale equity securities 3,967,101   (136,493)   8,807,742 711,465  
Unrealized transaction gain on foreign-currency denominated debt         0 (176,927)  
Changes in operating assets and liabilities:              
Accounts receivable, including from affiliated entities         (3,339,490) 5,212,478  
Prepaid expenses and other current assets, including from affiliated entities         (17,590,402) (52,141,119)  
Other assets         655,650 24,126,582  
Accounts payable and accrued expenses, including due to affiliated entities         58,090,822 10,022,647  
Accrued clinical trial expenses         (203,397) 465,819  
Deferred revenue, including from affiliated entity         8,953,565 48,824  
Operating lease right-of-use assets and liabilities, net         (1,272,391) (1,131,555)  
Grant funding liability, including from affiliated entity         (1,730,316) (636,155)  
Other liabilities         (14,826) 6,478  
Net cash used in operating activities         (112,410,075) (131,326,659)  
Cash flows from investing activities:              
Purchases of investments         (139,377,240) (307,857,113)  
Proceeds from sale or maturity of investments         153,122,784 83,466,967  
Purchases of capital assets         (717,212) (418,734)  
Investment in Geneos         (1,999,998) 0  
Net cash provided by (used in) investing activities         11,028,334 (224,808,880)  
Cash flows from financing activities:              
Proceeds from issuance of common stock, net of issuance costs         72,521,372 162,105,030  
Proceeds from stock option exercises         189,522 6,154,794  
Taxes paid related to net share settlement of equity awards         (1,349,733) (3,915,160)  
Net cash provided by financing activities         71,361,161 164,344,664  
Effect of exchange rate changes on cash and cash equivalents         (21,340) (11,941)  
Decrease in cash and cash equivalents         (30,041,920) (191,802,816)  
Cash and cash equivalents, beginning of period   $ 71,143,778   $ 250,728,118 71,143,778 250,728,118 $ 250,728,118
Cash and cash equivalents, end of period $ 41,101,858   $ 58,925,302   41,101,858 58,925,302 $ 71,143,778
Supplemental disclosures:              
Amounts accrued for purchases of fixed assets         67,645 0  
Interest paid         $ 533,487 $ 544,315